Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.

Inclusion Criteria: * 1.Diagnosed as lymphoma-Hemophagocytic Lymphohistiocytosis. * 2.Patients were older than 2 years of age. * 3.Estimated survival time ≥ 1 week. * 4.Cardiac ultrasound LVEF≥50%; No Active bleeding of the internal organs(digestive tract, lung, brain, etc.); If the patient has dyspnea, oxygenation index \>250. * 5.sign informed consent. Exclusion Criteria: * 1.Heart function above grade II (NYHA). * 2.Accumulated dose of doxorubicin above 400mg/m2 、epirubicin above 750mg/m2、pirarubicin above 800mg/m2 or the patients treated with anthracycline induced cardiovascular disease. * 3.Pregnancy or lactating Women. * 4.Allergic to pegylated liposomal doxorubicin or etoposide. * 5.Active bleeding of the internal organs. * 6.HIV antibody positivity. * 7.Acute or chronic active hepatitis B (HBsAg positivity, HBV DNA negative acceptable), acute or chronic active hepatitis C (HCV antibody negatively acceptable; HCV antibody positivity, HCV RNA negative acceptable). * 8.Participate in other clinical research at the same time. * 9.The researchers considered that patients are not suitable for the study.